Brevan Howard Capital Management’s Emergent Biosolutions EBS Stock Holding History

Brevan Howard Capital Management’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$326K	Buy	38,916 +6,303	+19%	+$52.7K	﹤0.01%	1668
2026 Q1	$271K	Buy	32,613 +22,526	+223%	+$233K	﹤0.01%	1691
2025 Q4	$125K	Sell	10,087 -3,813	-27%	-$40.9K	﹤0.01%	1661
2025 Q3	$123K	Sell	13,900 -4,824	-26%	-$37.5K	﹤0.01%	1842
2025 Q2	$119K	Buy	18,724 +5,743	+44%	+$32.9K	﹤0.01%	1774
2025 Q1	$63.1K	Buy	+12,981	New	+$107K	﹤0.01%	1082
2024 Q3	–	Sell	-29,058	Closed	-$198K	–	1214
2024 Q2	$198K	Buy	+29,058	New	+$125K	﹤0.01%	895
2023 Q4	–	Sell	-13,781	Closed	-$46.9K	–	1036
2023 Q3	$46.9K	Buy	+13,781	New	+$76.4K	﹤0.01%	366

Other funds holding EBS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

OHA

Oak Hill Advisors New York $701M AUM 78.4% 1-Year Est. Return

Brevan Howard Capital Management's EBS Position: Q2 2026 in Review

Brevan Howard Capital Management increased its Emergent Biosolutions (EBS) stake by 19% in Q2 2026, buying an estimated $52.7K and bringing the position to 38,916 shares worth $326K. The position accounts for ﹤0.01% of the portfolio, ranked #1668.

Brevan Howard Capital Management first reported a position in EBS in Q3 2023 and has held it in 8 quarters since. 194 funds tracked by Wall St. Rank hold EBS as of Q2 2026.

Brevan Howard Capital Management held 38,916 shares of Emergent Biosolutions worth $326K as of Q2 2026.
Brevan Howard Capital Management bought 6,303 Emergent Biosolutions shares in Q2 2026, an estimated $52.7K.
Emergent Biosolutions made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1668 holding.
Brevan Howard Capital Management first reported a position in Emergent Biosolutions in Q3 2023 and has held it in 8 quarters since.
194 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.